Ignite Creation Date:
2024-05-06 @ 12:50 AM
Last Modification Date:
2024-10-26 @ 10:55 AM
Study NCT ID:
NCT01664845
Status:
UNKNOWN
Last Update Posted:
2012-08-14
First Post:
2012-08-10
Brief Title:
Effects of Metformin Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance
Sponsor:
Kaohsiung Veterans General Hospital
Organization:
Kaohsiung Veterans General Hospital
Study Overview
Official Title:
Effects of Metformin Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance
Status:
UNKNOWN
Status Verified Date:
2012-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to investigate the treatment response of metformin Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus HCV
Detailed Description:
Current standard of treatment for HCV with pegylated interferonPeg-IFN-alpha and ribavirin can achieve sustained virological response SVR in only 60-90 of patients Insulin resistance is an important factor of non-response to combination therapy Metformin is a insulin sensitizer and can effectively reduce insulin resistance The aim of the study is to investigate the treatment response of metformin Peg-IFN and ribavirin combination therapy for chronic HCV
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None